Table 3. Geometric mean (%CV) day 14 telatinib and BAY 60–8246 pharmacokinetic parameters after oral administration of telatinib.

Telatinib
Dose	75 mg BID	150 mg BID	300 mg BID	600 mg BID	900 mg BID	1200 mg BID	1500 mg BID
n	4	6	6	11	12	6	12
Mesylate tablet	25 mg	25 mg	25 mg	150 mg	150 mg	150 mg	150 mg
Cmax (mg l−1)	0.212 (140%)	0.219 (80%)	0.389 (153%)	0.810 (87%)	1.275 (57%)	1.144 (40%)	0.964 (83%)
tmax (h)a	2.1 (2.0–3.1)	3.0 (0.52–5.5)	1.5 (0–8.5)	2.1 (1.0–4.2)	2.0 (0.5–8.1)	2.5 (1–4.3)	2.5 (0.6–6.0)
AUC0–tn (mg h l−1)	1.38 (150%)	1.75 (84%)	1.92 (142%)	5.43 (68%)	7.41 (51%)	7.10 (31%)	6.17 (80%)
AUC0–12 (mg h l−1)	1.39 (146%)	1.73 (81%)	2.86 (176%)b	5.43 (68%)	7.30 (52%)	7.26 (31%)	6.29 (84%)
t1/2 (h)	7.4 (33%)	10.9 (66%)†	8.0 (58%)b	8.7 (46%)	5.6 (62%)b	5.6 (100%)	6.6 (65%)
BAY 60–8246
Cmax (mg l−1)	0.02 (202%)	0.018 (89%)	0.021 (133%)	0.084 (140%)	0.216 (74%)	0.226 (87%)	0.102 (147%)
tmax (h)a	3.0 (0.5–6.0)	2.5 (1.0–12.3)	1.5 (0–8.5)	2.1 (0.6–10)	3.7 (1.0–8.6)	4.0 (2.1–4.3)	3.5 (0.5–6.1)
AUC0–tn (mg h l−1)	0.125 (333%)c	0.157 (74%)	0.115 (113%)b	0.650 (128%)	1.27 (79%)	1.66 (81%)	0.74 (155%)
AUC0–12 (mg h l−1)	0.153 (232%)	0.155 (72%)	0.219 (58%)b	0.650 (128%)	1.25 (80%)	1.71 (84%)	0.76 (160%)

AUC_0–12=area under the plasma concentration versus time curve from time 0–12 h; AUC_0–tn=area under the plasma concentration versus time curve from time 0 to last data point; BID=two times daily; C_max=maximum plasma concentration; %CV=percent coefficient of variation; t_max=time to reach maximum plasma concentration; t_1/2=terminal half-life.

^aMedian (range).

^bSample size reduced by 2.

^cSample size reduced by 1.